Skip to main content

Table 2 Intervention

From: Sclerotherapy and prolotherapy for chronic patellar tendinopathies - a promising therapy with limited available evidence, a systematic review

Author Year Study Type Substance Control Mean VAS Mean no of injections Serious Adverse Events
      pre post FU   
Sclerotherapy
 Alfredson 2004 prospective polidocanol 5 mg/ml na 79.7 19   2.7 none
 Gisslén 2006 casereport polidocanol 10 mg/ml na 90 0 0 1.0 none
 Hoksrud 2006 RCT polidocanol 10 mg/ml adrenaline 5 μg/ml+lidocaine hcl 5 mg/ml VISA VISA VISA 3.1 (intervention + crossover) none
 Willberg 2011 RCT polidocanol 10 mg/ml arthroscopic shaving 69 41.1 (17) na none
 Hoksrud 2012 prospective polidocanol 10 mg/ml na VISA VISA VISA 2.5 none
Prolotherapy
 Ryan 2011 prospective 25% dextrose solution na 51.1   25.8 median 4 none
 Topol 2011 RCT 12.5% dextrose solution lidocaine 10 mg/ml NPPS NPPS NPPS 3.8 none
  1. VAS Visual Analogue Scale, no number, FU Follow-up, RCT Randomized controlled trial, na not available, VISA Victorian Institute of Sport Assessment, NPPS Nirschl Pain Phase Scale
\